Less frequent dosing of drug for patients with bone metastas
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, use of the bisphosphonate drug zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years, according to a study appearing in JAMA....

Read more at : http://www.medicalnewstoday.com/releases/315045.php